GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alimera Sciences Inc (FRA:ASZ1) » Definitions » EV-to-EBIT

Alimera Sciences (FRA:ASZ1) EV-to-EBIT : -23.14 (As of May. 25, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Alimera Sciences EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Alimera Sciences's Enterprise Value is €194.12 Mil. Alimera Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-8.39 Mil. Therefore, Alimera Sciences's EV-to-EBIT for today is -23.14.

The historical rank and industry rank for Alimera Sciences's EV-to-EBIT or its related term are showing as below:

FRA:ASZ1' s EV-to-EBIT Range Over the Past 10 Years
Min: -4199.08   Med: -7.49   Max: 79.68
Current: -23.08

During the past 13 years, the highest EV-to-EBIT of Alimera Sciences was 79.68. The lowest was -4199.08. And the median was -7.49.

FRA:ASZ1's EV-to-EBIT is ranked worse than
100% of 672 companies
in the Drug Manufacturers industry
Industry Median: 16.985 vs FRA:ASZ1: -23.08

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Alimera Sciences's Enterprise Value for the quarter that ended in Mar. 2024 was €237.89 Mil. Alimera Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-8.39 Mil. Alimera Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -3.53%.


Alimera Sciences EV-to-EBIT Historical Data

The historical data trend for Alimera Sciences's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alimera Sciences EV-to-EBIT Chart

Alimera Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -18.30 -2,839.18 55.35 -6.40 -28.33

Alimera Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.00 -8.33 -16.83 -28.33 -28.51

Competitive Comparison of Alimera Sciences's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Alimera Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alimera Sciences's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alimera Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Alimera Sciences's EV-to-EBIT falls into.



Alimera Sciences EV-to-EBIT Calculation

Alimera Sciences's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=194.120/-8.39
=-23.14

Alimera Sciences's current Enterprise Value is €194.12 Mil.
Alimera Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-8.39 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alimera Sciences  (FRA:ASZ1) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Alimera Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-8.39/237.892679
=-3.53 %

Alimera Sciences's Enterprise Value for the quarter that ended in Mar. 2024 was €237.89 Mil.
Alimera Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-8.39 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alimera Sciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Alimera Sciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Alimera Sciences (FRA:ASZ1) Business Description

Traded in Other Exchanges
Address
6310 Town Square, Suite 400, Alpharetta, GA, USA, 30005
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.

Alimera Sciences (FRA:ASZ1) Headlines

No Headlines